Erratum: Quintás-cardama A, Kantarjian H, Garcia-Manero G, et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer. 2007;109(2):248–55.
Article first published online: 27 APR 2007
Copyright © 2007 American Cancer Society
Volume 109, Issue 12, page 2625, 15 June 2007
How to Cite
- Issue published online: 4 JUN 2007
- Article first published online: 27 APR 2007
In the article cited above, the dose of HHT should be 2.5 mg/m2, not 2 mg/m2.
HHT was administered at a rate of 1.25 mg/m2 s.c. twice daily for 13 days every 28 days until remission, not 14 days.
Results and conclusions of this article remain unchanged.
The authors regret these errors.